Goodwin congratulates Flow Neuroscience on receiving FDA approval of their breakthrough at-home brain-stimulation device for the treatment of major depressive disorder (MDD). FDA approval marks the first time clinicians in the US are able to prescribe an at-home non-drug therapy as both a stand-alone and an adjunctive treatment for adults with moderate to severe depression. Goodwin's Technology and Life Sciences teams were thrilled to assist Flow Neuroscience in bringing this breakthrough device to patients in the US
“Having worked with Flow Neuroscience since the early days, it has been a privilege to support the company through each stage of its journey,” said Andrew Harper, partner at Goodwin. “This world-first FDA approval marks an important milestone, and we’re proud to have guided Flow through each phase of its continued growth.”
Flow Neuroscience is pioneering a new category of at-home electric medicine and delivering drug-free, brain-based treatments for mental health. Founded in Sweden in 2016 by clinical psychologist Daniel Mansson and computational neuroscientist Erik Rehn, Flow developed the world’s first medically certified at-home transcranial direct current stimulation (tDCS) headset. Since its European launch in 2019, Flow has become the only CE-marked at-home tDCS treatment for depression used by the NHS, empowering more than 55,000 people to take control of their mental health. With FDA approval in 2025, the US joins the UAE, Australia, Brazil, the UK and EU as countries where Flow’s accessible depression treatment is available.
The Goodwin team that worked with Flow Neuroscience to launch their product in the US was led by Andrew Harper (Technology, Life Sciences), Steven Tjoe (FDA), Roger Cohen (Healthcare), Jacqueline Klosek (Data, Privacy, and Cybersecurity), Jacob Osborn (Global Trade), and Summer Brook Lawson (Technology, Life Sciences).
For more information on the approval, please read the press release.